44-1092G

antibody from Invitrogen Antibodies

Targeting: GYS1 GSY, GYS

Western blot (Data presented on provider website)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

44-1092G

Provider

Invitrogen Antibodies

Product name

Phospho-GYS1 (Ser641, Ser645) Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Storage

-20°C

References

Submitted references

Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice.

Gong Q, Hu Z, Zhang F, Cui A, Chen X, Jiang H, Gao J, Chen X, Han Y, Liang Q, Ye D, Shi L, Chin YE, Wang Y, Xiao H, Guo F, Liu Y, Zang M, Xu A, Li Y
Hepatology (Baltimore, Md.) 2016 Aug;64(2):425-38

---

Accelerated recovery of mitochondrial membrane potential by GSK-3β inactivation affords cardiomyocytes protection from oxidant-induced necrosis.

Sunaga D, Tanno M, Kuno A, Ishikawa S, Ogasawara M, Yano T, Miki T, Miura T
PloS one 2014;9(11):e112529

---

Translocation of glycogen synthase kinase-3β (GSK-3β), a trigger of permeability transition, is kinase activity-dependent and mediated by interaction with voltage-dependent anion channel 2 (VDAC2).

Tanno M, Kuno A, Ishikawa S, Miki T, Kouzu H, Yano T, Murase H, Tobisawa T, Ogasawara M, Horio Y, Miura T
The Journal of biological chemistry 2014 Oct 17;289(42):29285-96

---

Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse.

Nishino Y, Webb IG, Davidson SM, Ahmed AI, Clark JE, Jacquet S, Shah AM, Miura T, Yellon DM, Avkiran M, Marber MS
Circulation research 2008 Aug 1;103(3):307-14

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry analysis of Phospho-Glycogen Synthase [pSer641/pSer645] was done on HeLa cells treated with PMA (200nM, 20 minutes). Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with Phospho-Glycogen Synthase [pSer641/pSer645] Rabbit Polyclonal Antibody (441092G, red histogram) or with rabbit isotype control (yellow histogram) at 3-5 ug/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Goat Anti-Rabbit Secondary Antibody (A11008) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 Effects of inhibition of GSK-3beta on antimycin A-induced changes in DeltaPsi m and its recovery. A: Western blotting for Ser9-phospho- and total GSK-3beta in mitochondria, B: Effects of antimycin A (AA) on phospho-GSK-3beta level. C: TMRE fluorescence after AA treatment in vehicle- and LiCl-pretreated cells. Western blotting for Ser9-phospho-GSK-3beta, total GSK-3beta, Ser641/645-phospho-glycogen synthase (GS), non-phospho-GS and beta-actin (loading control) in total lysates of vehicle-treated and LiCl-treated cells. Treatments with 30 mM and 60 mM LiCl for 60 min induced phosphorylation of GSK-3beta and dephosphorylation of GS. Increased phosphorylation of GSK-3beta by LiCl reflects reduced activity of protein phosphatase 1, which is positively regulated by GSK-3beta activity. D: TMRE fluorescence after AA treatment in control siRNA- and GSK-3beta-siRNA-pretreated cells. NC = nicorandil. Treatment = time after onset of treatment with AA, Washout = time after washout of AA. *p